Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › LGVN

Longeveron

LGVN Rare disease Lead: Phase 2 ★ Read the deep dive → 14 Biotech Distilled articles ↓ 43 filings & releases ↓ Cash $10.1M (Jun 30, 2026) ↓ 14 verdicts ↓ 2 timing quotes ↓
CardiovascularMetabolicNeurology Cell

Market cap $5.8M 3.2M shares (vendor count, Nov 7, 2026) × $1.81 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Laromestrocel DCM Ph2/3 start2H 2026Laromestrocel DCM Ph2/3 start, 2H 2026, routine
  2. Company strategic review4Q 2026Company strategic review, 4Q 2026, routine
  3. Laromestrocel HLHS BLA filing2027Laromestrocel HLHS BLA filing, 2027, material
  4. Pediatric DCM Phase 2 registrational2027Pediatric DCM Phase 2 registrational, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$10.1M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$5.7M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$10.1M cash, runway fourth quarter of 2026 per the update of Oct 26, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (14)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (14 calls)

Every verdict Biotech Distilled has published on Longeveron, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-01-06 Watch Longeveron Inc (LGVN): Scientific Deep Dive for Lead and Pipeline Products The HLHS science is intriguing but the dilution gap is a structural barrier to entry; wait for the inevitable financing to clear before re-evaluating.
  2. 2026-01-30 Watch UPDATE: Longeveron (LGVN) - Regulatory Momentum & Manufacturing Moat FDA meeting and Japan patent strengthen the regulatory and manufacturing story, but the balance sheet risk remains the gatekeeper.
  3. 2026-02-07 Watch UPDATE : Longeveron (LGVN) - Rare Pediatric Disease PRV Program Reauthorized PRV legislative security improves asset attractiveness but does not solve the immediate cash crisis; still waiting for the capital raise.
  4. 2026-02-14 Watch UPDATE: Longeveron (LVGN) - The Financial Fire Alarm is Ringing The 8-K confirms an acute cash crisis with 50% pay cuts and furloughs; a dilutive financing is imminent and the disciplined move is to stay on the sidelines.
  5. 2026-02-28 Watch UPDATE: Longeveron (LGVN) - Scientific Validation vs. Financial Reality Cell Stem Cell publication is scientific validation but doesn't pay the bills; the dilution gap remains the primary focus and the stock should be avoided until financing clears.
  6. 2026-03-07 Watch UPDATE: Longeveron (LGVN) - The Reverse Stock Split and the Dilution Trap The reverse split proxy reveals the mechanism for massive dilution and confirms active financing negotiations; stay on the sidelines until the deal is done and dust settles.
  7. 2026-03-15 Speculative buy speculative UPDATE: Longeveron (LGVN) - Surviving the Gap (But Pawning the Crown Jewel) Near-term bankruptcy risk is off the table with $15M upfront financing bridging to Q3 2026 HLHS data, but the cap table is massively diluted and 50% of PRV upside has been signed away.
  8. 2026-03-21 Speculative buy speculative UPDATE: Longeveron (LGVN) - The 10-K Autopsy The 10-K confirms the cash crunch narrative; financing extended runway into Q4 2026 and the only thing that matters now is the ELPIS II Phase 2b trial readout.
  9. 2026-05-09 Avoid UPDATE: Longeveron (LGVN) - The FDA Pulls the Pivotal Rug FDA revoked pivotal status for ELPIS II and rejected the primary endpoint, materially breaking both legs of the catalyst-trade thesis and making the BLA path in 2027 murky.
  10. 2026-05-14 Avoid UPDATE: Longeveron (LGVN) - The ATM Trap Snaps Shut The ATM facility is mechanically frozen below $0.80 while the stock trades at $0.75, further narrowing financing optionality and hardening the May 8 downgrade thesis.
  11. 2026-08-13 Avoid UPDATE: Longeveron (LGVN) - Four Weeks of Oxygen Left $10.1M cash against a $5.7M quarterly burn, a frozen ATM, and a Nasdaq deadline nine days after the September data window creates a single-point failure scenario.
  12. 2026-08-24 Avoid UPDATE: Longeveron (LGVN) - They Spent the Bullet Before the Data The 1-for-10 reverse split was executed before the data to protect the Nasdaq listing, spending the only structural fix and opening a one-year re-breach trapdoor; nothing about the science or cash changed.
  13. 2026-09-17 Avoid UPDATE: Longeveron (LGVN) - The Envelope Opened and It Was Empty ELPIS II missed both the primary endpoint (p=0.8336) and the sponsor composite; the company is now a strategic-alternatives shell with roughly one quarter of cash and a delisting trapdoor.
  14. 2026-10-27 Avoid UPDATE: Longeveron (LGVN) - The Envelope Gets Re-Opened A pre-specified MACE secondary hit p=0.043 on nine events after the primary failed, reopening scientific optionality but not fixing the cash runway or regulatory path; any spike into AHA is a volatility event not a re-rating.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (43)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)